Xinomiline
| Code | Size | Price |
|---|
| TAR-T35183-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Xinomiline is a biochemical.
CAS:
52832-91-4
Formula:
C5H10N2O
Molecular Weight:
114.148
Purity:
0.98
SMILES:
CC1(C)COC(N)=N1
References
Takai K, Enomoto T. Discovery and Development of Muscarinic Acetylcholine M(4) Activators as Promising Therapeutic Agents for CNS Diseases. Chem Pharm Bull (Tokyo). 2018;66(1):37-44. doi: 10.1248/cpb.c17-00413. Review. PubMed PMID: 29311510.
Rand?kov? A, Dolej?? E, Rudajev V, Zim??k P, Dole?al V, El-Fakahany EE, Jakub?k J. Role of membrane cholesterol in differential sensitivity of muscarinic receptor subtypes to persistently bound xanomeline. Neuropharmacology. 2018 May 1;133:129-144. doi: 10.1016/j.neuropharm.2018.01.027. PubMed PMID: 29407765.
van der Westhuizen ET, Spathis A, Khajehali E, Jorg M, Mistry SN, Capuano B, Tobin AB, Sexton PM, Scammells PJ, Valant C, Christopoulos A. Assessment of the molecular mechanisms of action of novel 4-phenylpyridine-2-one and 6-phenylpyrimidin-4-one allosteric modulators at the M1 muscarinic acetylcholine receptors. Mol Pharmacol. 2018 Apr 24. pii: mol.118.111633. doi: 10.1124/mol.118.111633. [Epub ahead of print] PubMed PMID: 29691279.
Tammenmaa-Aho I, Asher R, Soares-Weiser K, Bergman H. Cholinergic medication for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2018 Mar 19;3:CD000207. doi: 10.1002/14651858.CD000207.pub2. Review. PubMed PMID: 29553158.